TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Five Year Follow-up of Internet-based Cognitive Behaviour Therapy for Social Anxiety Disorder
Brief Summary: Social anxiety disorder (SAD) is one of the most prevalent anxiety disorders in the western world. Cognitive behavioural therapy (CBT) is the psychological treatment that has the largest empirical support. However, the availability to CBT is very limited in Sweden due to lack of therapists with proper training. Therefore it is important to evaluate alternative forms of treatment that are more time efficient. One of these methods is Internet based self-help therapy, which has proven to be an effective treatment for social anxiety disorder.

In this study, the investigators aim to conduct a follow-up assessment five years after completed Internet-based CBT. Participants received treatment within the context of a randomised controlled trial conducted in 2005. Thus, in the present study there will be no treatment interventions, only assessment.


Options:
A: Arm Label: Internet-based CBT; Type: N/A; Interventions: N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT via the Internet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: CBT group therapy | Intervention Type: BEHAVIORAL; Name: CBT via the Internet; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: CBT group therapy; Assigned to Arm(s): 2
C: Arm Label: iSOFIE; Type: EXPERIMENTAL; Interventions: Other: iSOFIE | Arm Label: Waitlist control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: iSOFIE; Assigned to Arm(s): iSOFIE
D: Arm Label: Internet CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavior therapy (CBT). | Arm Label: Group CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Group CBT | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavior therapy (CBT).; Assigned to Arm(s): Internet CBT | Intervention Type: BEHAVIORAL; Name: Group CBT; Assigned to Arm(s): Group CBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition and Physical Activity in Patients With Cerebrovascular Disease
Brief Summary: The study will provide evidence of eating habits and physical activity in cerebrovascular patients in Luxembourg and of the degree to which these habits may be changed acutely (after one month) and in the long run (after 4 months) by intensive counselling. Furthermore the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition, and on surrogate parameters for stroke will be assessed.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Ethanol-free beverage | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: ethanol | Intervention Type: OTHER; Name: ethanol; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Ethanol-free beverage; Assigned to Arm(s): 1
B: Arm Label: Low- polyphenol diet; Type: OTHER; Interventions: Other: Two portions of fruit and vegetables per day (excluding berries and dark chocolate) | Arm Label: High-polyphenol diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate. | Intervention Type: OTHER; Name: Two portions of fruit and vegetables per day (excluding berries and dark chocolate); Assigned to Arm(s): Low- polyphenol diet | Intervention Type: OTHER; Name: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.; Assigned to Arm(s): High-polyphenol diet
C: Arm Label: Glass; Type: ACTIVE_COMPARATOR; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Arm Label: Can 1; Type: EXPERIMENTAL; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Arm Label: Can 2; Type: EXPERIMENTAL; Interventions: Other: Can 1, Other: Can 2, Other: Glass | Intervention Type: OTHER; Name: Can 1; Assigned to Arm(s): Can 1, Can 2, Glass | Intervention Type: OTHER; Name: Can 2; Assigned to Arm(s): Can 1, Can 2, Glass | Intervention Type: OTHER; Name: Glass; Assigned to Arm(s): Can 1, Can 2, Glass
D: Arm Label: Luxembourg diet + wine; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Arm Label: conventional + wine; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: conventional; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: Luxembourg diet; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional diet +/- wine; Assigned to Arm(s): conventional, conventional + wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Luxembourg variant of Mediterranean diet + physical activity +/- wine; Assigned to Arm(s): Luxembourg diet, Luxembourg diet + wine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition and Physical Activity in Patients With Cerebrovascular Disease
Brief Summary: The study will provide evidence of eating habits and physical activity in cerebrovascular patients in Luxembourg and of the degree to which these habits may be changed acutely (after one month) and in the long run (after 4 months) by intensive counselling. Furthermore the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition, and on surrogate parameters for stroke will be assessed.


Options:
A: Arm Label: Luxembourg diet + wine; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Arm Label: conventional + wine; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: conventional; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: Luxembourg diet; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional diet +/- wine; Assigned to Arm(s): conventional, conventional + wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Luxembourg variant of Mediterranean diet + physical activity +/- wine; Assigned to Arm(s): Luxembourg diet, Luxembourg diet + wine
B: Intervention Type: BEHAVIORAL; Name: Dietary intake; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle factors; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Blood biomarkers; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Health; Assigned to Arm(s): N/A | Intervention Type: GENETIC; Name: DNA; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Mental well-being; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nutrition and Physical Activity in Patients With Cerebrovascular Disease
Brief Summary: The study will provide evidence of eating habits and physical activity in cerebrovascular patients in Luxembourg and of the degree to which these habits may be changed acutely (after one month) and in the long run (after 4 months) by intensive counselling. Furthermore the influence of intensive counselling and of the consumption of red wine on cerebrovascular risk factors, cognition, and on surrogate parameters for stroke will be assessed.


Options:
A: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
D: Arm Label: Luxembourg diet + wine; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Arm Label: conventional + wine; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: conventional; Type: OTHER; Interventions: Dietary Supplement: Conventional diet +/- wine | Arm Label: Luxembourg diet; Type: OTHER; Interventions: Dietary Supplement: Luxembourg variant of Mediterranean diet + physical activity +/- wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Conventional diet +/- wine; Assigned to Arm(s): conventional, conventional + wine | Intervention Type: DIETARY_SUPPLEMENT; Name: Luxembourg variant of Mediterranean diet + physical activity +/- wine; Assigned to Arm(s): Luxembourg diet, Luxembourg diet + wine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Brief Summary: Background:

Obesity is associated with a high prevalence of chronic kidney disease.The glomerular hyperfiltration associated with obesity may play a role in the pathogenesis of obesity associated chronic kidney disease. Attenuation of hyperfiltration by pharmacological means may slow down the development and progression of chronic renal failure. The investigators have previously shown that acetazolamide, a proximally acting diuretic that activates tubuloglomerular feedback(TGF) by increasing solute delivery to the Macula DENSA, abates glomerular hyperfiltration. The present study was designed to test the hypothesis that this decrease in hyperfiltration is specific to acetazolamide and not due to a non specific diuretic effect. The aim of the present study is to compare the effects of furosemide and acetazolamide on glomerular hemodynamics in subjects with severe obesity.

Methods:

A randomized double-blind crossover controlled design will be used. Fifteen obese subjects and ten subjects with normal body weight will participate in the study. Obese subjects will undergo measurement of glomerular filtration rate (GFR)(inulin clearance), renal plasma flow (RPF) (p-aminohippuric acid clearance), filtration fraction, fractional excretion of lithium (FE LI) and blood pressure, before and after intravenous administration of furosemide 2 mg. and acetazolamide 5 mg/kg BW. Ten subjects with normal body weight will undergo measurement of renal function without administration of diuretics.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: weight reduction; Type: EXPERIMENTAL; Interventions: Behavioral: weight reduction | Intervention Type: BEHAVIORAL; Name: weight reduction; Assigned to Arm(s): weight reduction
B: Arm Label: Furosemide first, then Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Furosemide first, then Acetazolamide | Arm Label: Acetazolamide first, then Furosemide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide first, then Furosemide | Intervention Type: DRUG; Name: Furosemide first, then Acetazolamide; Assigned to Arm(s): Furosemide first, then Acetazolamide | Intervention Type: DRUG; Name: Acetazolamide first, then Furosemide; Assigned to Arm(s): Acetazolamide first, then Furosemide
C: Arm Label: IBW; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus extended release | Arm Label: ABW; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus extended release | Intervention Type: DRUG; Name: tacrolimus extended release; Assigned to Arm(s): ABW, IBW
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bardoxolone Methyl; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl: 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bardoxolone Methyl: 20 mg; Assigned to Arm(s): Bardoxolone Methyl

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Retrospective Epidemiological Study to Map Out Patients With Chronic Obstructive Pulmonary Disease (COPD) and Describe COPD Health Care in Real-Life Primary Care During the First Ten Years of the 21th Century
Brief Summary: The aim of this study is to describe COPD health care and to assess demographics, concurrent diseases and mortality and the use of pharmaceuticals for a chronic obstructive pulmonary disease (COPD) population in real life in primary care during the last ten years.


Options:
A: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
B: Intervention Type: DRUG; Name: Budesonide/formoterol pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Budesonide pMDI; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Formoterol Turbuhaler; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: N/A; Interventions: N/A
D: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Protocol to Collect the Outcome and Safety of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Study P06029 (Phase 3; Protocol No. P06031)
Brief Summary: The purpose of this follow-up study is to collect the outcome and safety of FTET cycles after the embryos are cryopreserved in P06029 (NCT01144416). P06029 was a study in which a single injection of corifollitropin alfa (SCH 900962) was compared with daily recombinant follicle stimulating hormone (recFSH) injections in women aged 35 to 42 years undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).


Options:
A: Arm Label: Corifollitropin alfa 150 μg; Type: EXPERIMENTAL; Interventions: Biological: Corifollitropin alfa | Arm Label: recFSH 300 IU; Type: ACTIVE_COMPARATOR; Interventions: Biological: recFSH (follitropin beta) | Intervention Type: BIOLOGICAL; Name: Corifollitropin alfa; Assigned to Arm(s): Corifollitropin alfa 150 μg | Intervention Type: BIOLOGICAL; Name: recFSH (follitropin beta); Assigned to Arm(s): recFSH 300 IU
B: Arm Label: Blastocyst transfer in PTEC cycle; Type: EXPERIMENTAL; Interventions: Procedure: Embryo cryopreservation | Arm Label: Fresh blastocyst transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh blastocyst transfer | Intervention Type: PROCEDURE; Name: Embryo cryopreservation; Assigned to Arm(s): Blastocyst transfer in PTEC cycle | Intervention Type: PROCEDURE; Name: Fresh blastocyst transfer; Assigned to Arm(s): Fresh blastocyst transfer
C: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
D: Arm Label: Frozen Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Arm Label: Fresh Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Intervention Type: OTHER; Name: PGD; Assigned to Arm(s): Fresh Embryo Transfer with PGD, Frozen Embryo Transfer with PGD

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Follow-up Protocol to Collect the Outcome and Safety of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Study P06029 (Phase 3; Protocol No. P06031)
Brief Summary: The purpose of this follow-up study is to collect the outcome and safety of FTET cycles after the embryos are cryopreserved in P06029 (NCT01144416). P06029 was a study in which a single injection of corifollitropin alfa (SCH 900962) was compared with daily recombinant follicle stimulating hormone (recFSH) injections in women aged 35 to 42 years undergoing controlled ovarian stimulation (COS) prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: Blastocyst transfer in PTEC cycle; Type: EXPERIMENTAL; Interventions: Procedure: Embryo cryopreservation | Arm Label: Fresh blastocyst transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh blastocyst transfer | Intervention Type: PROCEDURE; Name: Embryo cryopreservation; Assigned to Arm(s): Blastocyst transfer in PTEC cycle | Intervention Type: PROCEDURE; Name: Fresh blastocyst transfer; Assigned to Arm(s): Fresh blastocyst transfer
C: Arm Label: Corifollitropin alfa 150 μg; Type: EXPERIMENTAL; Interventions: Biological: Corifollitropin alfa | Arm Label: recFSH 300 IU; Type: ACTIVE_COMPARATOR; Interventions: Biological: recFSH (follitropin beta) | Intervention Type: BIOLOGICAL; Name: Corifollitropin alfa; Assigned to Arm(s): Corifollitropin alfa 150 μg | Intervention Type: BIOLOGICAL; Name: recFSH (follitropin beta); Assigned to Arm(s): recFSH 300 IU
D: Arm Label: frozen-embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: freezing embryos by vitrification, Drug: buserelin, Drug: recombinant FSH, Drug: human chorionic gonadotropin (pregnyl) | Arm Label: fresh embryo transfer; Type: ACTIVE_COMPARATOR; Interventions: Procedure: fresh embryo transfers, Drug: buserelin, Drug: recombinant FSH, Drug: human chorionic gonadotropin (pregnyl) | Intervention Type: PROCEDURE; Name: freezing embryos by vitrification; Assigned to Arm(s): frozen-embryo transfer | Intervention Type: PROCEDURE; Name: fresh embryo transfers; Assigned to Arm(s): fresh embryo transfer | Intervention Type: DRUG; Name: buserelin; Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer | Intervention Type: DRUG; Name: recombinant FSH; Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer | Intervention Type: DRUG; Name: human chorionic gonadotropin (pregnyl); Assigned to Arm(s): fresh embryo transfer, frozen-embryo transfer

Answer: C